EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond peak VO2: oxygen uptake at the first ventilatory threshold and clinical outcomes in transthyretin cardiac amyloidosis

Antonio Kösters, Mahshid Eslami, Elisabetta Salvioni, Nikita Ermolaev, Lisa Seilinger, Mauro Contini, Carlo Vignati, Robin Willixhofer, Simona Costantino, Mariusz Grzeda, Fiorella Puttini, Massimo Mapelli und 2 weitere

European Heart Journal Open · 13.11.2026

DOI: 10.1093/ehjopen/oeag207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 13.11.2026. Verfasst von Antonio Kösters und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Oxygen uptake at the first ventilatory threshold (VT1) can be expressed as an absolute value (VO2VT1-abs), as a percentage of predicted peak VO2 (VO2VT1-%pred), or as a percentage of observed peak VO2 (VO2VT1-%obs). We compared their prognostic performance in transthyretin cardiac amyloidosis (ATTR-CM). Methods and Results Adults with ATTR-CM undergoing baseline cardiopulmonary exercise testing at two centres were studied. Endpoints were all-cause mortality and death or heart failure (HF) hospitalisation. Censoring-aware 2-year discrimination and age- and sex-adjusted Cox associations were assessed. Incremental model fit and discrimination beyond age, sex, peak VO2, and VE/VCO2 slope were evaluated, with bootstrap internal validation. Among 182 patients, VT1 was identifiable in 173 (95.1%). Mortality follow-up was available in 162 patients (44 deaths), and composite follow-up in 157 (66 events). Per 1-standard-deviation decrease, VO2VT1-abs and VO2VT1-%pred were associated with mortality (hazard ratio [HR] 2.86, 95% confidence interval [CI] 1.77–4.63; and HR 2.50, 95% CI 1.61–3.87; both P<0.001) and the composite endpoint (HR 2.25, 95% CI 1.53–3.31; and HR 2.38, 95% CI 1.65–3.43; both P<0.001). VO2VT1-%obs was not associated with either endpoint. Adding VO2VT1-abs or VO2VT1-%pred improved mortality model fit (likelihood-ratio P=0.019 and P=0.034), but bootstrap 95% CIs for both gains in C-index included zero. Severe-limitation analyses were exploratory, without significant interactions.

Conclusion

Absolute and predicted-normalised VT1 were associated with outcomes; non-proportional hazards warrant caution for absolute-VT1 mortality. Improved model fit does not establish improved predictive discrimination, clinical utility, or added value beyond comprehensive ATTR-CM risk stratification. External validation is required.

Zitieren

APA

Kösters, A., Eslami, M., Salvioni, E., Ermolaev, N., Seilinger, L., Contini, M., Vignati, C., Willixhofer, R., Costantino, S., Grzeda, M., Puttini, F., Mapelli, M., Agostoni, P., & Eslam, R. B. (2026). Beyond peak VO2: oxygen uptake at the first ventilatory threshold and clinical outcomes in transthyretin cardiac amyloidosis. European Heart Journal Open. https://doi.org/10.1093/ehjopen/oeag207

Vancouver

Kösters A, Eslami M, Salvioni E, Ermolaev N, Seilinger L, Contini M, et al. Beyond peak VO2: oxygen uptake at the first ventilatory threshold and clinical outcomes in transthyretin cardiac amyloidosis. European Heart Journal Open. 2026. doi:10.1093/ehjopen/oeag207

BibTeX
@article{Ksters2026,
  author = {Kösters, Antonio and Eslami, Mahshid and Salvioni, Elisabetta and Ermolaev, Nikita and Seilinger, Lisa and Contini, Mauro and Vignati, Carlo and Willixhofer, Robin and Costantino, Simona and Grzeda, Mariusz and Puttini, Fiorella and Mapelli, Massimo and Agostoni, Piergiuseppe and Eslam, Roza Badr},
  title = {Beyond peak VO2: oxygen uptake at the first ventilatory threshold and clinical outcomes in transthyretin cardiac amyloidosis},
  journal = {European Heart Journal Open},
  year = {2026},
  doi = {10.1093/ehjopen/oeag207}
}
Kostenlos starten →